PL3717455T3 - Sposoby wytwarzania modulatorów błonowego regulatora przewodnictwa związanego z mukowiscydozą - Google Patents

Sposoby wytwarzania modulatorów błonowego regulatora przewodnictwa związanego z mukowiscydozą

Info

Publication number
PL3717455T3
PL3717455T3 PL18816468.5T PL18816468T PL3717455T3 PL 3717455 T3 PL3717455 T3 PL 3717455T3 PL 18816468 T PL18816468 T PL 18816468T PL 3717455 T3 PL3717455 T3 PL 3717455T3
Authority
PL
Poland
Prior art keywords
methods
cystic fibrosis
conductance regulator
membrane conductance
related membrane
Prior art date
Application number
PL18816468.5T
Other languages
English (en)
Inventor
Berenice LEMERCIER LEWANDOWSKI
Robert Lewis
Adam Looker
Adam Morgan
Stefanie Roeper
Michael Ryan
Juan Gabriel Solsona Rocabert
Nathan WILDE
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60673754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3717455(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL3717455T3 publication Critical patent/PL3717455T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/08—Preparation of nitro compounds by substitution of hydrogen atoms by nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/43—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/34—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having amino groups and esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C07C37/0555—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group being esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/16—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/06—Alkylated phenols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C07C39/16—Bis-(hydroxyphenyl) alkanes; Tris-(hydroxyphenyl)alkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C68/00—Preparation of esters of carbonic or haloformic acids
    • C07C68/02—Preparation of esters of carbonic or haloformic acids from phosgene or haloformates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C68/00—Preparation of esters of carbonic or haloformic acids
    • C07C68/06—Preparation of esters of carbonic or haloformic acids from organic carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicines Containing Plant Substances (AREA)
PL18816468.5T 2017-12-01 2018-11-30 Sposoby wytwarzania modulatorów błonowego regulatora przewodnictwa związanego z mukowiscydozą PL3717455T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382829 2017-12-01
PCT/US2018/063451 WO2019109021A1 (en) 2017-12-01 2018-11-30 Processes for making modulators of cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
PL3717455T3 true PL3717455T3 (pl) 2025-03-24

Family

ID=60673754

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18816468.5T PL3717455T3 (pl) 2017-12-01 2018-11-30 Sposoby wytwarzania modulatorów błonowego regulatora przewodnictwa związanego z mukowiscydozą

Country Status (15)

Country Link
US (2) US11708331B2 (pl)
EP (2) EP3717455B1 (pl)
KR (2) KR102768380B1 (pl)
CN (2) CN117924170A (pl)
AU (2) AU2018375186B2 (pl)
BR (1) BR112020010335A2 (pl)
CA (1) CA3082444A1 (pl)
ES (1) ES3003533T3 (pl)
HR (1) HRP20241608T1 (pl)
HU (1) HUE069984T2 (pl)
IL (2) IL305169B2 (pl)
MA (1) MA51206A (pl)
PL (1) PL3717455T3 (pl)
SG (1) SG11202004264VA (pl)
WO (1) WO2019109021A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
HUE047354T2 (hu) * 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
RS61150B1 (sr) 2016-12-09 2020-12-31 Vertex Pharma Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutske kompozicije, postupci lečenja, i postupak za dobijanje modulatora
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
KR102768380B1 (ko) 2017-12-01 2025-02-13 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막관통 조절 인자의 제조 방법
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
MX2022001828A (es) 2019-08-14 2022-06-08 Vertex Pharma Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4259139A1 (en) 2020-12-10 2023-10-18 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN119947720A (zh) 2022-05-16 2025-05-06 弗特克斯药品有限公司 治疗囊性纤维化的方法
CN119894906A (zh) 2022-09-15 2025-04-25 爱杜西亚药品有限公司 大环cftr调节剂
JP2025530377A (ja) 2022-09-15 2025-09-11 イドルシア・ファーマシューティカルズ・リミテッド 大環状ｃｆｔｒ調節剤とｃｆｔｒコレクター及び／又はｃｆｔｒポテンシエーターとの合剤
WO2025166342A1 (en) 2024-02-04 2025-08-07 Vertex Pharmaceuticals Incorporated Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis
EP4648753A1 (en) 2024-02-07 2025-11-19 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3110738A (en) * 1963-11-12 Nitration of aromatic compounds
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ES2193921T3 (es) 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
DK1492789T3 (da) 2002-04-08 2006-09-11 Pfizer Tropanderivater som CCR5-modulatorer
EP1515978A1 (en) 2002-06-20 2005-03-23 IC Vec Limited Sulfur-containing phospholipid derivatives
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
JP2009521468A (ja) 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
AU2006331565A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in CFTR assays and methods therewith
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
WO2007134279A2 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
EP2139848A1 (en) 2007-04-26 2010-01-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
CN101855218A (zh) 2007-09-13 2010-10-06 康塞特医药品有限公司 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成
NZ620027A (en) 2007-09-14 2015-05-29 Vertex Pharma Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
LT3170818T (lt) 2007-12-07 2020-05-25 Vertex Pharmaceuticals Incorporated Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
SMT201800074T1 (it) 2008-08-13 2018-05-02 Vertex Pharma Composizione farmaceutica di n-[2,4-bis(1,1-dimetiletil)-5-idrossifenil]-1,4-diidro-4-ossochinolin-3-carbossammide e sua somministrazione
UA104005C2 (ru) 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
AU2009308232B2 (en) 2008-10-23 2016-02-04 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
HRP20130536T1 (en) 2008-10-23 2013-07-31 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
CN102227424B (zh) 2008-10-23 2013-08-14 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
US20110257223A1 (en) 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
HRP20181261T1 (hr) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Modulatori regulatora transmembranske provodljivosti cistične fibroze
ES2654414T3 (es) 2009-03-20 2018-02-13 Vertex Pharmaceuticals Incorporated Proceso de preparación de moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8471029B2 (en) 2010-03-19 2013-06-25 Vertex Pharmaceutical Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
EP2560649A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
AU2011242454A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
AU2011242457A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
CN102234275B (zh) 2010-04-27 2015-12-16 溧阳合誉药物科技有限公司 治疗失眠的氘代咪唑并[1,2-a]吡啶衍生物、制备方法及其应用
EP2575814A1 (en) 2010-05-20 2013-04-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
WO2012027731A2 (en) 2010-08-27 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
PT2709986T (pt) 2011-05-18 2017-06-26 Concert Pharmaceuticals Inc Derivados deuterados de ivacaftor
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
AU2012278976B2 (en) * 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
EP2773349A1 (en) 2011-11-02 2014-09-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2013185112A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
SMT201800590T1 (it) 2012-11-02 2019-01-11 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
MY178621A (en) * 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
CN109364075B (zh) * 2012-11-21 2021-10-29 顶点制药（欧洲）有限公司 氘化cftr增效剂
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
CN105658216A (zh) 2013-10-28 2016-06-08 雀巢产品技术援助有限公司 用于治疗消化不良的单酰基甘油和脂溶性营养物质
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
MX388470B (es) 2015-09-21 2025-03-20 Vertex Pharmaceuticals Europe Ltd Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.
CA2999529A1 (en) * 2015-09-25 2017-03-30 Vertex Pharmaceuticals (Europe) Limited Deuterated cftr potentiators
WO2017060779A1 (en) * 2015-10-06 2017-04-13 Optimus Drugs (P) Limited Industrial process for making an ivacaftor and its intermediates
CA3041819A1 (en) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
US20180125838A1 (en) 2016-10-27 2018-05-10 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
KR102768380B1 (ko) 2017-12-01 2025-02-13 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막관통 조절 인자의 제조 방법
FI3880197T3 (fi) * 2018-11-14 2023-05-04 Vertex Pharma Menetelmiä kystisen fibroosin hoitamiseksi

Also Published As

Publication number Publication date
IL274763B2 (en) 2024-01-01
EP3717455C0 (en) 2024-11-20
CA3082444A1 (en) 2019-06-06
US12024491B2 (en) 2024-07-02
IL305169A (en) 2023-10-01
CN111479804A (zh) 2020-07-31
CN117924170A (zh) 2024-04-26
US11708331B2 (en) 2023-07-25
HUE069984T2 (hu) 2025-04-28
US20240166607A1 (en) 2024-05-23
MA51206A (fr) 2020-10-07
KR102768380B1 (ko) 2025-02-13
IL274763A (en) 2020-07-30
KR102720000B1 (ko) 2024-10-21
SG11202004264VA (en) 2020-06-29
IL305169B1 (en) 2025-03-01
AU2018375186B2 (en) 2023-07-20
KR20240153418A (ko) 2024-10-22
EP4484402A2 (en) 2025-01-01
AU2023248117B2 (en) 2025-08-14
KR20200096560A (ko) 2020-08-12
EP4484402A3 (en) 2025-07-02
CN111479804B (zh) 2023-12-22
IL274763B1 (en) 2023-09-01
IL305169B2 (en) 2025-07-01
US20200290972A1 (en) 2020-09-17
AU2018375186A1 (en) 2020-06-18
EP3717455B1 (en) 2024-11-20
ES3003533T3 (en) 2025-03-10
EP3717455A1 (en) 2020-10-07
HRP20241608T1 (hr) 2025-01-31
BR112020010335A2 (pt) 2020-11-10
WO2019109021A1 (en) 2019-06-06
AU2023248117A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
PL3717455T3 (pl) Sposoby wytwarzania modulatorów błonowego regulatora przewodnictwa związanego z mukowiscydozą
EP3436446C0 (en) CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS
DK3203840T3 (da) Modulatorer af cystisk fibrose-transmembrankonduktansregulator
IL275049B (en) Processes for making modulators of cystic fibrosis transmembrane conductance regulator
DK3681864T3 (da) Modulatorer af det cystisk fibrose-transmembranledningsevneregulatorprotein og anvendelsesfremgangsmåder
DK3551622T3 (da) Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren
IL251623B (en) Co-crystal of cftr protein modulators
EP3430024A4 (en) THERAPEUTIC MEMBRANE VESICLES
PL3481942T3 (pl) Sposoby hodowania organoidów
HUE053832T2 (hu) Üreges szálas membrán on-line szárítása
DOP2018000293A (es) Moduladores de moléculas pequeñas de pantothenate kinases
BR112017014213A2 (pt) moduladores de ciclopropanocarboxamida do regulador da condutância transmembrana da fibrose cística.
EP3550851A4 (en) ACOUSTIC DEVICE
EP3563296A4 (en) ZERO SHOT LEARNING USING A MULTI-SCALE MANIFOLD ALIGNMENT
EP3447759A4 (en) MUSICAL INSTRUMENTS
FR3053053B1 (fr) Modeles de la dermatite atopique juvenile
DK3606953T3 (da) Fgfr3-bindende molekyler
EP3466301A4 (en) COSMETIC TOOL
EP3474397A4 (en) SWITCHING
HK40089592A (en) Modulators of cystic fibrosis transmembrane conductance regulator
PL3609860T3 (pl) Sposoby wytwarzania fenoksyetanolu
CU20160007S4 (es) Instrumento musical
HK40005326A (en) Modulators of cystic fibrosis transmembrane conductance regulator protein
UA34434S (uk) Електрогітара
UA35241S (uk) Електрогітара